John Thompson
Direktor/Vorstandsmitglied bei NERVGEN PHARMA CORP.
Vermögen: - $ am 31.05.2024
Aktive Positionen von John Thompson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
NERVGEN PHARMA CORP. | Direktor/Vorstandsmitglied | 13.04.2022 | - |
Independent Dir/Board Member | 13.04.2022 | - | |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - |
Karriereverlauf von John Thompson
Ehemalige bekannte Positionen von John Thompson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ANTHERA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.12.2016 | 30.06.2018 |
Vorstandsvorsitzender | 01.12.2016 | 30.06.2018 | |
Geschäftsführer | 07.01.2016 | 01.12.2016 | |
Präsident | 07.01.2016 | 30.06.2018 | |
TETRAPHASE PHARMACEUTICALS, INC. | Geschäftsführer | 04.02.2014 | 31.12.2015 |
PFIZER, INC. | Vertrieb & Marketing | 01.01.2003 | 01.01.2010 |
Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | 17.07.2018 | - |
Präsident | 17.07.2018 | - | |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 11.01.2011 | - |
Ausbildung von John Thompson
McMaster University | Undergraduate Degree |
University of Notre Dame | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 8 |
Kanada | 3 |
Operativ
Chief Executive Officer | 3 |
Director/Board Member | 3 |
Chief Operating Officer | 2 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
PFIZER, INC. | Health Technology |
ANTHERA PHARMACEUTICALS, INC. | Health Technology |
NERVGEN PHARMA CORP. | Health Technology |
Private Unternehmen | 4 |
---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- John Thompson
- Erfahrung